The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical Cancer Research

• Publication date

  2003-08-15

• Fields of study

  Medicine

• Identifiers
  PMID 12960140
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiangiogenic Chemotherapeutic Agents

  2004cited by this paper
• Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?

  2003cited by this paper
• Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.

  2002cited by this paper
• SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice

  2002cited by this paper
• Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival

  2001cited by this paper
• Redefining the target: chemotherapeutics as antiangiogenics.

  2001cited by this paper
• Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs.

  2001cited by this paper
• Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.

  2001cited by this paper
• Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

  2000cited by this paper
• SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

  2000influential reference
• Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

  2000cited by this paper
• Aquaporins and the respiratory system: advice for a lung investigator.

  2000cited by this paper
• Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

  2000cited by this paper
• Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

  2000cited by this paper
• Anticancer drug targets: growth factors and growth factor signaling.

  2000cited by this paper
• New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.

  2000cited by this paper
• PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

  2000cited by this paper
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

  2000cited by this paper
• Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.

  2000cited by this paper
• Clinical applications of angiogenic growth factors and their inhibitors

  1999cited by this paper
• Molecular and biological properties of vascular endothelial growth factor

  1999cited by this paper
• VEGFs, receptors and angiogenesis.

  1999cited by this paper
• The prognostic significance of angiogenesis in epithelial ovarian carcinoma.

  1999cited by this paper
• Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.

  1998cited by this paper
• Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models

  1998cited by this paper
• Anti-angiogenic therapies in cancer clinical trials.

  1998cited by this paper
• Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors.

  1998cited by this paper
• Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice.

  1998cited by this paper
• Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.

  1998cited by this paper
• Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.

  1998cited by this paper
• Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.

  1998cited by this paper
• Molecular characterisation of a panel of human ovarian carcinoma xenografts.

  1998cited by this paper
• Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.

  1997cited by this paper
• Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers.

  1997cited by this paper
• Angiogenic protein expression in advanced epithelial ovarian cancer.

  1997cited by this paper
• Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells.

  1996cited by this paper
• Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor.

  1996cited by this paper
• The microtubule-affecting drug paclitaxel has antiangiogenic activity.

  1996cited by this paper
• A systems approach to cancer therapy

  1996cited by this paper
• Drug therapy : paclitaxel (Taxol)

  1995cited by this paper
• Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

  1995cited by this paper
• Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo.

  1995cited by this paper
• Tumor angiogenesis in advanced stage ovarian carcinoma.

  1995cited by this paper
• Clinical Applications of Research on Angiogenesis

  1995cited by this paper
• Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.

  1995cited by this paper
• Paclitaxel (taxol)

  1995cited by this paper
• Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.

  1995cited by this paper
• Vascular permeability factor gene expression in normal and neoplastic human ovaries.

  1994cited by this paper
• Soluble intercellular adhesion molecule-1 (ICAM-1) is released into the serum and ascites of human ovarian carcinoma patients and in nude mice bearing tumour xenografts.

  1994cited by this paper
• Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.

  1993cited by this paper
• Medical progress : cancer of the ovary

  1993cited by this paper
• Taxol in ovarian cancer

  1993cited by this paper
• Effects of modulation of basic fibroblast growth factor on tumor growth in vivo.

  1993cited by this paper
• Cancer of the ovary.

  1993cited by this paper
• Cancer of the ovary.

  1993cited by this paper
• Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas.

  1992cited by this paper
• Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma.

  1991cited by this paper
• Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner.

  1991cited by this paper
• Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy

  1989cited by this paper
• Recent developments in the cell biology of basic fibroblast growth factor

  1989cited by this paper
• Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation.

  1988cited by this paper
• Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines.

  1988cited by this paper
• Angiogenic factors.

  1987cited by this paper

• The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance.

  2025cites this paper
• Increasing Tumor Extracellular pH by an Oral Alkalinizing Agent Improves Antitumor Responses of Anti-PD-1 Antibody: Implication of Relationships between Serum Bicarbonate Concentrations, Urinary pH, and Therapeutic Outcomes.

  2021cites this paper
• SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications

  2020cites this paper
• New Isatin–Indole Conjugates: Synthesis, Characterization, and a Plausible Mechanism of Their in vitro Antiproliferative Activity

  2020cites this paper
• DDDT_A_227862 483..495

  2020cites this paper
• Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.

  2019cites this paper
• Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds.

  2018cites this paper
• Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy.

  2018cites this paper
• Luteinizing hormone compromises the in vivo anti-tumor effect of cisplatin on human epithelial ovarian cancer cells.

  2017cites this paper
• Multi-kinase inhibitors, AURKs and cancer

  2016cites this paper
• Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling

  2015cites this paper
• Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics

  2015cites this paper
• Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin

  2015cites this paper
• Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling

  2015cites this paper
• Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales

  2013cites this paper
• Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents

  2013cites this paper
• The VEGFC/VEGFR3 pathway in the malignancy of ovarian carcinoma

  2013cites this paper
• The role of pathology in the development and evaluation of murine xenograft models of human cancer

  2013cites this paper
• SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model

  2012cites this paper
• Fibroblast Growth Factor Receptor Inhibition Synergizes With Paclitaxel and Doxorubicin in Endometrial Cancer Cells

  2012cites this paper
• Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models

  2012cites this paper
• Augmentation of Chemotherapeutic Infusion Effect by TSU-68, an Oral Targeted Antiangiogenic Agent, in a Rabbit VX2 Liver Tumor Model

  2012cites this paper
• Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.

  2012cites this paper
• Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.

  2011cites this paper
• CHAPTER 4 TYROSINE KINASE INHIBITOR SU 6668 REPRESSES CHONDROSARCOMA GROWTH VIA ANTI-ANGIOGENESIS IN VIVO

  2011cites this paper
• Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer

  2010cites this paper
• Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice.

  2010cites this paper
• Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer.

  2010cites this paper
• Targeting tumor vasculature

  2009cites this paper
• Aflibercept in epithelial ovarian carcinoma.

  2009cites this paper
• Beyond chemotherapy: targeted therapies in ovarian cancer

  2009cites this paper
• VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion.

  2009cites this paper
• VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition

  2009cites this paper
• Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion

  2008cites this paper
• Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer

  2008cites this paper
• Development of antiangiogenic agents for ovarian cancer

  2008cites this paper
• Anti‐tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model

  2008cites this paper
• Targeting signaling pathways in ovarian cancer

  2008cites this paper
• Combination therapy of tyrosine kinase receptor inhibitor TSU-68 (SU6668) and paclitaxel inhibits subcutaneous xenografts of endometrial cancer.

  2008cites this paper
• Non-Peptidic Mimetics as Cancer-Sensitizing Agents

  2008cites this paper
• Shinshu University Institutional Repository SOAR-IR

  2008cites this paper
• Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition

  2008cites this paper
• epidermal growth factor receptor inhibition cancer cells : therapeutic implications and synergism with contribute to the malignant phenotype of non-small cell lung Fibroblast growth factor receptor-mediated signals

  2008cites this paper
• Strategies for suppressing angiogenesis in gynecological cancers.

  2007cites this paper
• Quantitative contrast enhanced ultrasound and CT assessment of tumor response to antiangiogenic therapy in rats.

  2007cites this paper
• Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.

  2007cites this paper
• Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo

  2007cites this paper
• The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma.

  2007cites this paper
• Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC).

  2007cites this paper
• FGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopod.

  2007cites this paper
• Tumor’host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds

  2007cites this paper
• Targeting the tumor vasculature strategies for combination therapy

  2007cites this paper
• Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy

  2007cites this paper
• Suppression of ovarian cancer by muscle‐mediated expression of soluble VEGFR‐1/Flt‐1 using adeno‐associated virus serotype 1‐derived vector

  2007cites this paper
• Microtubule-targeting agents in angiogenesis: where do we stand?

  2006cites this paper
• Paclitaxel prodrugs: toward smarter delivery of anticancer agents.

  2006cites this paper
• Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.

  2006cites this paper
• The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis

  2006cites this paper
• Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

  2006cites this paper
• Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells.

  2006cites this paper
• Anti‐angiogenic drugs: from bench to clinical trials

  2006cites this paper
• Disruption of Fibroblast Growth Factor Signal Pathway Inhibits the Growth of Synovial Sarcomas: Potential Application of Signal Inhibitors to Molecular Target Therapy

  2005cites this paper
• Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective.

  2005cites this paper
• New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

  2005cites this paper
• Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU‐68)

  2005cites this paper
• Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer

  2005cites this paper
• Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics.

  2005cites this paper
• Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy

  2005cites this paper
• Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust.

  2003cites this paper